Suchergebnisse - "Kaseb, Ahmed"

PubPharm (272)

1

Phase I Trial of SPECT-Guided Liver-Directed Radiotherapy for Patients with Low Functional Liver Volume

enthalten in: JNCI cancer spectrum | 2024

von Chang, E. | Wong, F. | Chasen, B. | +29

2

Systemic Therapy for Advanced Hepatocellular Carcinoma : ASCO Guideline Update

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Gordan, J. | Kennedy, E. | Abou-Alfa, G. | +21

3

Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer

enthalten in: bioRxiv.org | 2024

von Dogra, P. | Shinglot, V. | Ruiz-Ramírez, J. | +11

4

Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer

enthalten in: medRxiv : the preprint server for health sciences | 2024

von Dogra, P. | Shinglot, V. | Ruiz-Ramírez, J. | +11

5

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : final results of a randomised phase 3 study

enthalten in: The lancet. Gastroenterology & hepatology | 2024

von Yau, T. | Kaseb, A. | Cheng, A. | +19

6

Genome-wide association study identifies high-impact susceptibility loci for HCC in North America

enthalten in: Hepatology (Baltimore, Md.) | 2024

von Hassan, M. | Li, D. | Han, Y. | +50

7

Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort

enthalten in: Investigational new drugs | 2024

von Emiloju, O. | Yin, J. | Koubek, E. | +19

8

Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort

enthalten in: Investigational new drugs | 2024

von Emiloju, O. | Yin, J. | Koubek, E. | +19

9

Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection

enthalten in: Frontiers in pharmacology | 2024

von Maen, A. | Gok Yavuz, B. | Mohamed, Y. | +12

10

Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma

enthalten in: Journal of hepatocellular carcinoma | 2024

von Chamseddine, S. | LaPelusa, M. | Xiao, L. | +10

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[28]